#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl